US FDA’s Drug Center Losing Shortages, Controlled Substance Leadership With Throckmorton Retirement

Throckmorton is known for enhancing the FDA’s drug shortage work by building bridges between the compliance and quality teams, as well as opioid oversight.

Douglas Throckmorton will retire in January. (Shutterstock)

When Douglas Throckmorton, a long-time deputy director in the Center for Drug Evaluation and Research, retires in the coming months, the US Food and Drug Administration will lose a significant voice for the center’s drug shortage and controlled substance policy, as well as a prominent unifying force.

More from US FDA

More from Geography